| Document |
Document Title |
|
WO/2024/009215A1 |
Provided herein are novel compounds, e.g., those of Formula (I), as GCN2 inhibitors. Also provided are pharmaceutical compositions including one or more of the novel compounds, and pharmaceutical uses thereof. Compounds provided herein c...
|
|
WO/2024/008128A1 |
Provided are a sulfoximine compound having an FGFR inhibitory effect, a pharmaceutical composition comprising said sulfoximine compound, and a use thereof. Specifically provided are a sulfoximine compound as represented by formula (I) wh...
|
|
WO/2024/010015A1 |
Compounds represented by general formula (1), the compounds having strong inhibitory action against mPGES-1 and being useful as active ingredients for pharmaceuticals for the treatment of inflammation and the like.
|
|
WO/2024/009977A1 |
Provided is a type-I crystal of a free form of 4-(4-(3-((2-(tert-butylamino)ethyl)amino)-6-(5-(trifluoromet
hyl)-1,3,4-oxadiazol-2-yl)piperidin-2-yl)piperidin-1-yl)-5,5
-dimethyl-5H-pyrrolo[2,3-d]pyrimidin-6(7H)-one that has, in a powder...
|
|
WO/2024/010782A1 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...
|
|
WO/2024/011136A1 |
Described herein are crystalline forms of 1-(5-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7
-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fl
uorocyclopropyl)urea adipate, and solvates thereof.
|
|
WO/2024/007520A1 |
Provided are an organic compound and use thereof. The organic compound has a structure of H-L-Ar, wherein H has a structure represented by formula 1-1 or formula 1-2. In formula 1-1 and formula 1-2, A1 and A2 are identically or different...
|
|
WO/2024/008909A1 |
The present invention relates to novel compounds of Formula (I) (cyanophenyl/cyanopyridinyl- 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine amide compounds) for treating and/or preventing infection or diseases caused by coronavirus. The...
|
|
WO/2024/007883A1 |
The present invention belongs to the field of medicines and provides a class of thiazolamine-diazabicyclooctanone conjugated derivatives and use thereof. The compound provided by the present invention has good and broad-spectrum inhibiti...
|
|
WO/2024/008196A1 |
The present invention provides a class of compounds of general formula I and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, the present invention provides a compound having a structure ...
|
|
WO/2024/008722A2 |
The present invention relates to compounds useful for modulating Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). The invention also relates to the compounds for use in treatment of conditions related to loss of function of TR...
|
|
WO/2024/008122A1 |
The present invention belongs to the field of chemical pharmaceuticals, and provided are a PI3K inhibitor, a preparation method therefor, and a use thereof. The PI3K inhibitor of the present invention is a compound as represented by form...
|
|
WO/2024/008178A1 |
Provided are a compound of formula (I), and a stereoisomer, tautomer, deuterated product or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and an application...
|
|
WO/2024/009308A1 |
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.
|
|
WO/2024/008088A1 |
Disclosed are a class of compounds as TRK inhibitor drugs or RET inhibitor drugs and use thereof. Specifically, disclosed is use of a compound represented by formula (G), or an isotope-labeled compound thereof, or an optical isomer, a ge...
|
|
WO/2024/007976A1 |
A compound represented by formula (I), a chiral enantiomer thereof or pharmaceutically acceptable salts thereof, and a preparation method therefor, an intermediate used for preparing the compound represented by formula (I), the chiral en...
|
|
WO/2024/002206A1 |
Provided is a bifunctional compound, or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein the bifunctional compound is represented by Formula (I) : ABM-L-CLM (I); wherein: ABM is an androgen rec...
|
|
WO/2024/002205A1 |
Provided is a bifunctional compound, or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein the bifunctional compound is represented by Formula (I) : ABM-L-CLM (I); wherein: ABM is an androgen rec...
|
|
WO/2024/002112A1 |
The present invention relates to use of a compound represented by formula (I) in resisting feline coronavirus or calicivirus infection. The compound represented by formula (I) efficiently inhibits the replication of feline coronavirus or...
|
|
WO/2023/009835A9 |
The present disclosure provides antibody conjugates (e.g., antibody-drug conjugates (ADCs)) specific for MUC1. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same. Also provided ...
|
|
WO/2024/006559A1 |
Compounds are provided for inhibiting NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectiv...
|
|
WO/2024/005516A1 |
The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent for...
|
|
WO/2024/006971A2 |
Disclosed herein are compounds and compositions comprising the compounds of Formula I (I) wherein all variables are as defined herein. Further disclosed are methods for using the above compounds and compositions comprising the above comp...
|
|
WO/2024/006445A1 |
The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions co...
|
|
WO/2024/006916A1 |
Provided herein are compounds useful as inhibitors of Janus kinase (JAK) proteins and in treating JAK-related diseases.
|
|
WO/2024/005339A1 |
The present invention relates to: a salt (camsylate salt) of D(+)10-camphorsulfonic acid and a triazolopyrazine derivative of chemical formula 1; a pharmaceutical composition comprising the salt; a method for preparing the salt; and a th...
|
|
WO/2024/002378A1 |
The present invention provides an HPK1 kinase inhibitor, and the preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), where the definition of each group is as described in the d...
|
|
WO/2024/006970A2 |
Disclosed herein are compounds and compositions comprising said compounds as disclosed herein. Further disclosed are methods for using the above compounds and compositions comprising the above compounds for the prevention, amelioration, ...
|
|
WO/2024/006376A1 |
The disclosure provides solid forms, e.g. salts and polymorphs, of the compound of Formula (I) and uses thereof. Also provided are the methods of making the solid forms and pharmaceutical formulations comprising the solid forms.
|
|
WO/2024/002263A1 |
Disclosed are a series of amino-substituted heteroaryl and use thereof, and in particular, disclosed are a compound represented by formula (IV) and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/002377A1 |
Provided is a class of compounds with methyltransferase inhibitory activity. Specifically, provided is a class of compounds with PRMT5 inhibitory activity. The compounds can be used for preparing a pharmaceutical composition for treating...
|
|
WO/2024/002157A1 |
Provided are FGFR2 and FGFR3 inhibitors of Formula (I) and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with FGFR2 and/or FGFR3.
|
|
WO/2024/003208A1 |
The invention relates to a compound of formula (I) as SIK modulators for the treatment or prophylaxis of rheumatoid arthritis, juvenile rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, giant cel...
|
|
WO/2024/001487A1 |
The present invention relates to the technical field of green, clean and efficient catalysis, and in particular, to a method for synthesizing a cyclic carbonate from carbon dioxide and an epoxy compound by means of a catalytic reaction a...
|
|
WO/2024/006974A2 |
Disclosed herein are compounds and compositions comprising the compounds of Formula I (I) wherein all variables are as defined herein. Further disclosed are methods for using the above compounds and compositions comprising the above comp...
|
|
WO/2024/002934A1 |
The present invention relates to 8-heterocyclic-3-(phenylsulfonyl)-[1,2,3] triazolo[1,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof as well as to their uses in methods of reducing the virulence of bacteria (...
|
|
WO/2024/006879A1 |
Provided herein are inhibitors of ubiquitin-specific-processing Protease 1 (USP1), their pharmaceutical compositions, and methods of use for treating diseases or disorders, such as cancers described herein.
|
|
WO/2024/006016A1 |
An apparatus may include: a flow path defined by a conduit; and a functional polymer disposed in the conduit, wherein the functional polymer comprises a polymer and a macrocycle, wherein the macrocycle is grafted to the polymer by an ami...
|
|
WO/2024/006461A1 |
The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-
5-cyano-3,4-dihydroxytetrahydrofuran-2-yl...
|
|
WO/2024/005343A1 |
The present invention relates to salts (mesylates) of a methanesulfonic acid and a triazolopyrazine derivative of chemical formula 1, a pharmaceutical composition comprising same, a preparation method for the salt, and therapeutic use of...
|
|
WO/2024/006781A1 |
The application relates to bifunctional compounds of the general formula I-3' which act as degraders of the estrogen receptor alpha(ERα) and are useful for treating disorders associated with ERα-mediated transcription regulation such a...
|
|
WO/2024/002935A1 |
The present invention relates to 3-(phenylsulfonyl)-[1,2,3] triazolo[1,5a]quinazolin- 5(4H)-one derivatives and pharmaceutical compositions thereof as well as to their uses in methods of reducing the virulence of bacteria (preferably Sta...
|
|
WO/2024/002024A1 |
The present invention provides a class of compounds represented by formula (I), or tautomers, stereoisomers, or pharmaceutically acceptable salts thereof. The compounds of the present invention have a strong MAT2A inhibitory effect and h...
|
|
WO/2024/004619A1 |
An embodiment of the present invention provides: a curable composition containing a radical polymerization initiator represented by formula (1) and a radically polymerizable compound; a method for producing a cured product; a film; an op...
|
|
WO/2024/002289A1 |
This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the degrading target proteins a...
|
|
WO/2024/002376A1 |
The present invention provides a class of compounds with inhibitory activity against methyltransferases. Particularly, the present invention provides a class of compounds with inhibitory activity against PRMT5. The compounds can be used ...
|
|
WO/2024/006883A1 |
The present invention provides salt forms, and compositions and methods thereof, useful for treating various conditions, such as cancer, by the administration of small molecule therapeutics acting as kinase inhibitors.
|
|
WO/2024/002373A1 |
The present invention relates to a substituted pyrimidine-fused ring inhibitor, a method for preparing same, and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I). Further disclos...
|
|
WO/2024/006287A2 |
Disclosed herein are compound of Formula I, Formula II, or Formula III: or a pharmaceutically acceptable salt and/or solvate of any one or more thereof, pharmaceutical compositions including such compounds, and methods of treating diseas...
|
|
WO/2023/249968A1 |
The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also prov...
|
